Clinical Trials at University of Kansas Cancer Center

As of July 2026, 86 paid clinical trials are recruiting at University of Kansas Cancer Center, located at 3901 RAINBOW BOULEVARD, MAIL STOP 3002, KANSAS CITY, KS 66160-0001, phone (913) 588-6074 in Kansas City, Kansas. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

86 clinical trials at University of Kansas Cancer Center

·Clear filters·↓ Download CSV

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

167 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554393·Phase 2·Recruiting

Apply to this trial

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

for Anatomic Stage IV Breast Cancer AJCC v8

262 locations incl. Tucson

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06500455·Phase 3·Recruiting

Apply to this trial

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

129 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06672146·Phase 2·Recruiting

Apply to this trial

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

for Non-Muscle Invasive Bladder Urothelial Carcinoma

132 locations incl. Fayetteville

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06770582·Phase 2·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

276 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03739814·Phase 2·Recruiting

Apply to this trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for Prostate Adenocarcinoma

402 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT05946213·Phase 3·Recruiting

Apply to this trial

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

for Metastatic Head and Neck Squamous Cell Carcinoma

177 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06589804·Phase 3·Recruiting

Apply to this trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for Metastatic Salivary Gland Carcinoma

152 locations incl. Dublin

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05408845·Phase 2·Recruiting

Apply to this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

for Lung Non-Small Cell Carcinoma

248 locations incl. Jonesboro

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06116682·Phase 2·Recruiting

Apply to this trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

for Diffuse Large B-Cell Lymphoma

87 locations incl. Tucson

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05633615·Phase 2·Recruiting

Apply to this trial

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

for Grade 2 Meningioma

198 locations incl. Anaheim

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT03180268·Phase 3·Recruiting

Apply to this trial

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

for Recurrent Head and Neck Squamous Cell Carcinoma

178 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 79

Code: NCT04671667·Phase 2·Recruiting

Apply to this trial

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

for Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

100 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07195734·Phase 2·Recruiting

Apply to this trial

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

for Retroperitoneal Sarcoma

109 locations incl. Phoenix

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Sex: All·Age: 18+

Code: NCT04031677·Phase 3·Recruiting

Apply to this trial

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

for AL Amyloidosis

117 locations incl. Goodyear

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06022939·Phase 3·Recruiting

Apply to this trial

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

for Castration-Resistant Prostate Carcinoma

107 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06632977·Phase 2·Recruiting

Apply to this trial

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

for Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7

140 locations incl. Tucson

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT03493425·Phase 2·Recruiting

Apply to this trial

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

for Buccal Mucosa Squamous Cell Carcinoma

106 locations incl. Gilbert

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT04333537·Phase 2, Phase 3·Recruiting

Apply to this trial

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

for Resectable Intrahepatic Cholangiocarcinoma

Drug: Durvalumab

58 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06050252·Phase 2·Recruiting

Apply to this trial

Vitamin D for Prostate Endocrine Therapy

for Stage I Prostate Cancer AJCC v8

51 locations incl. Newark

Sponsor: University of Rochester

Sex: Male·Age: 50+

Code: NCT05838716·Phase 3·Recruiting

Apply to this trial

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

for Anatomic Stage IV Breast Cancer AJCC v8

58 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06500481·Phase 3·Recruiting

Apply to this trial

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

for Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

17 locations incl. Tampa

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05172245·Phase 1·Recruiting

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

for Astrocytoma, IDH-Mutant, Grade 2

43 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06860594·Phase 1·Recruiting

Apply to this trial

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

for Extensive Stage Lung Small Cell Carcinoma

Drug: Atezolizumab

43 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06287775·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

for Metastatic Colorectal Carcinoma

22 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05803382·Phase 1·Recruiting

Apply to this trial

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

for Malignant Solid Neoplasm

36 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642611·Phase 3·Recruiting

Apply to this trial

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

for Advanced Malignant Solid Neoplasm

36 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05327010·Phase 2·Recruiting

Apply to this trial

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

for Locally Advanced Pancreatic Adenocarcinoma

Drug: Peposertib

44 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04172532·Phase 1, Phase 2·Recruiting

Apply to this trial

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

for Colo-rectal Cancer

Drug: Cemiplimab

9 locations incl. Gainesville

Sponsor: NSABP Foundation Inc

Sex: All·Age: 18+

Code: NCT07058012·Phase 2·Recruiting

Apply to this trial

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

for Recurrent Multiple Myeloma

Drug: Teclistamab

14 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06465316·Phase 1·Recruiting

Apply to this trial

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

for Recurrent Hairy Cell Leukemia

Drug: Venetoclax

21 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06311227·Phase 2·Recruiting

Apply to this trial

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

for Acute Myeloid Leukemia

22 locations incl. Orange

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 75

Code: NCT05886049·Phase 1·Recruiting

Apply to this trial

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

for Advanced Malignant Solid Neoplasm

23 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05691491·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

for Recurrent Ovarian High Grade Serous Adenocarcinoma

27 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT04633239·Phase 1·Recruiting

Apply to this trial

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for Autoimmune Disease

Drug: Nivolumab

51 locations incl. Sacramento

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03816345·Phase 1·Recruiting

Apply to this trial

Cold Water Irrigation Therapy as an Adjunct to Indomethacin for Post-Endoscopic Retrograde Cholangiopancreatography(ERCP) Pancreatitis

for Pancreatitis

1 location in Kansas City

Sponsor: University of Kansas Medical Center

Sex: All·Age: 20+

Code: NCT07330284·Recruiting

Apply to this trial

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

for Breast Atypical Hyperplasia

3 locations incl. Kansas City

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 45 - 74·Accepts healthy volunteers

Code: NCT06195306·Phase 2·Recruiting

Apply to this trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

for Metastatic Colorectal Adenocarcinoma

Drug: Bevacizumab

13 locations incl. Gainesville

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06696768·Phase 1·Recruiting

Apply to this trial

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

for Chronic Graft-versus-host Disease (cGVHD)

Drug: Ruxolitinib

5 locations incl. Miami

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All·Age: 18+

Code: NCT06660355·Phase 2·Recruiting

Apply to this trial

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

for Breast Atypical Hyperplasia

4 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 35+

Code: NCT05941520·Phase 2·Recruiting

Apply to this trial